Genetic and pharmacological strategies aiming at blockade of the S100a8/a9‐Nlrp3‐IL‐1β signaling axis have been shown to dampen myelopoiesis and improve cardiac function after myocardial infarction.19, 25, 42, 43. This evidence concerns the gene IGKV1D-22 and myocardial infarction.